ARS Pharmaceuticals, Inc. (SPRY) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• ARS Pharmaceuticals (SPRY) Q1 2026: NEFI Prescription Volume Triples, Payer Access Set for July Inflection
  May 15, 2026
• ARS Pharmaceuticals (SPRY) Q4 2025: NEFI Penetrates 22,500 Prescribers as Refill Dynamics Set Up 2026 Growth
  March 09, 2026
• ARS Pharmaceuticals (SPRY) Q3 2025: NEFI U.S. Revenue Jumps 2.5x, DTC and Global Expansion Set Stage for 2026
  November 10, 2025
• ARS Pharmaceuticals (SPRY) Q2 2025: NEFI Scripts Jump 180% as DTC and Pediatric Launches Expand Reach
  August 13, 2025
• ARS Pharmaceuticals (SPRY) Q1 2025: NEFI Coverage Doubles to 57%, Tipping Point for Needle-Free Epinephrine
  July 03, 2025

Browse all companies